WebJun 1, 2024 · Background: Mantle cell lymphoma (MCL) is an aggressive B cell malignancy, and accounts for ≈6% of non-Hodgkin lymphomas. Despite high initial … WebDec 7, 2015 · A Psyrri, P Economopoulou, U Dafni: Reply to D. Adkins et al J Clin Oncol 33: 1225 – 1226, 2015 Link, Google Scholar: 28. D Adkins, J Ley, TM Wildes, etal: RTOG 0522: Huge investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur? J Clin Oncol 33: 1223 – 1224, 2015 Link, Google ...
Assessment of the Validity of Nuclear-Localized Androgen ... - JAMA
WebOct 29, 2024 · Ann Oncol 26: 1300-1304, 2015 Medline, Google Scholar: 41. Atkinson BJ, Kalra S, Wang X, et al: Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 191: 611-618, 2014 Crossref, Medline, Google Scholar: 42. WebWe conducted network meta-analysis based on a random-effects consistency model as described by White et al 13 following a multivariate metaregression approach to pool evidence from direct and indirect comparisons. In addition, consistency between indirect and direct comparisons was evaluated. ... Ann Oncol. 2015;26(3):477-485. doi:10.1093 ... do jpmc make in-person job offers
Phase III study comparing oxaliplatin plus S-1 with …
WebAug 31, 2015 · FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status. WebPaz-Ares L, et al. Ann Oncol. 2024; 28:270–277. Note: Unlike the other studies that reflect data from the overall population, LUX-Lung 3, -6 and -7 show values for patients with … WebBackground: We evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric … doj plea bargain on centercede